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Background: Addition of deep hyperthermia to radiotherapy results in improved local
control (LC) and overall survival compared to radiotherapy alone in cervical carcinoma
patients. Based on preclinical data, the time interval between radiotherapy, and
hyperthermia is expected to influence treatment outcome. Clinical studies addressing
the effect of time interval are sparse. The repercussions for clinical applications are
substantial, as the time between radiotherapy and hyperthermia should be kept as short
as possible. In this study, we therefore investigated the effect of the time interval between
radiotherapy and hyperthermia on treatment outcome.
Methods: We analyzed all primary cervical carcinoma patients treated between
1996 and 2016 with thermoradiotherapy at our institute. Data on patients, tumors
and treatments were collected, including the thermal dose parameters TRISE and
CEM43T90. Follow-up data on tumor status and survival as well as late toxicity were
collected. Data was analyzed using Cox proportional hazards analysis and Kaplan
Meier analysis.
Results: 400 patients were included. Kaplan Meier and univariate Cox analysis showed
no effect of the time interval (range 30–230min) on any clinical outcome measure.
Besides known prognostic factors, thermal dose parameters TRISE and CEM43T90 had
a significant effect on LC. In multivariate analysis, the thermal dose parameter TRISE (HR
0.649; 95% CI 0.501–0.840) and the use of image guided brachytherapy (HR 0.432;
95% CI 0.214–0.972), but not the time interval, were significant predictors of LC and
disease specific survival.
Conclusions: The time interval between radiotherapy and hyperthermia, up to 4 h, has
no effect on clinical outcome. These results are re-ensuring for our current practice of
delivering hyperthermia within maximal 4 h after radiotherapy.
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INTRODUCTION
Cervical carcinoma is the sixth most common cancer in
women in The Netherlands and the fourth most common
cancer in women worldwide(1). Local control (LC) is a
prerequisite for definitive cure and contributes highly to patient
survival (2). For women with locally advanced cervical cancer,
radiotherapy combined with cisplatin-based chemotherapy is
the standard treatment (3). In patients unfit for chemotherapy
or patients with large FIGO IIB or higher FIGO stage disease,
radiotherapy can also be combined with hyperthermia -also
called thermoradiotherapy-, instead of chemotherapy. In the
latter patients, the addition of hyperthermia to radiotherapy
results in comparable outcome compared to chemoradiotherapy
in terms of LC and overall survival (OS), while treatment-related
toxicity is not increased (4–7). A direct clinical comparison
between thermo- and chemoradiotherapy is lacking to date.
Nevertheless, a recent network meta-analysis by Datta et al
showed that both thermo- as well as chemoradiotherapy were
the modalities with the best comprehensive impact on clinical
endpoints in cervical cancer patients(8).
At our institute patients are treated standard with
thermoradiotherapy in case of a locally advanced (FIGO
IIB and higher) tumor or when patients are unfit for or refuse
Cisplatin chemotherapy. Induction chemotherapy is indicated
in case the tumor is 6 cm or more, lymph node metastases
are 2 cm or larger and in case of positive para-aortic lymph
nodes. If induction chemotherapy is applied, local treatment
consists of thermoradiotherapy, which is given sequentially to
the chemotherapy.
Hyperthermia, defined as an elevation of tissue temperature
in the range of 40–44 degrees Celsius, is a potent sensitizer of
radiotherapy (9, 10). The biological mechanisms of hyperthermia
in combination with radiotherapy are diverse and include
increased oxygenation, induction of direct cell death and
immune stimulation (11, 12). In addition, hyperthermia inhibits
the repair of DNA double strand breaks, which are the main
inducers of tumor cell death following ionizing radiation (13, 14).
The sensitizing effect of hyperthermia in radiotherapy is
determined by the thermal dose, which is the net result of
the temperature rise in the target area and the duration
of heating (15, 16). Two clinical thermal dose parameters
are often investigated are: the CEM43T90 and the linearized
TRISE (15). We have previously shown that CEM43T90
and TRISE are independent predictors for LC and Disease
Specific Survival (DSS) in a large cohort of cervical cancer
patients (15).
For practical reasons and a pre-clinically observed improved
therapeutic ratio, hyperthermia is usually applied following
external beam radiotherapy treatment (17–19). The effect of
the time interval between radiotherapy and hyperthermia on
clinical outcome is subject of active investigation. Preclinical
evidence suggests a synergistic effect of hyperthermia with
radiation when administered within 4 h, with an enhanced
effect using shorter time intervals (17, 20). However, the size
and relevance of this effect in the clinical setting has not
been investigated thoroughly (21, 22). At our institution the
hyperthermia treatment is applied within 4 h after the external
beam fraction. The waiting time within these 4 h, though,
is completely random to date, depending on machine and
personnel availability.
Recently, a retrospective analysis showed a significant
association between a short time interval and a poor LC and OS
(23). Confirmation of this relation would have great impact: all
centers treating cervical cancer patients with thermoradiotherapy
should reduce the time interval. Therefore, the aim of our study
was to analyze the effect of time interval between radiotherapy
and hyperthermia on patient outcome in larger cohort of patients
with cervical carcinoma cancer.
METHODS
Patient Population
The research protocol for this investigation was approved by
the medical ethics committee of Erasmus MC Cancer Institute,
Rotterdam, theNetherlands (MEC-2018-1081). Patients included
were diagnosed with primary cervical cancer and treated
with curative intent using thermoradiotherapy at our institute
between August 1996 and December 2016. Excluded were
patients receiving concurrent chemotherapy, fewer than four of
the five intended hyperthermia sessions and patients receiving
radiotherapy at other institutes because of a lack of data on
follow-up. All patients had a histologically confirmed cervical
carcinoma and were staged by the International Federation
of Gynecology and Obstetrics (FIGO) clinical staging system,
including investigation under general anesthesia with cystoscopy
and lymph node staging using CT and/or MRI and/or PET-
CT. Indications for primary thermoradiotherapy at Erasmus MC
Cancer Institute are locally advanced tumors: “lateral” FIGO
IIB (>50% parametrial invasion), IIIA, IIIB, and IVA, patients
unfit or refusing platinum-based chemotherapy and patients
receiving induction chemotherapy. Indications for induction
chemotherapy include primary tumor size of 6 cm or larger,
pelvic lymph node metastases of 2 cm or larger or para-aortic
lymph node metastases (24). Induction chemotherapy consisted
of 6-weekly cycles of cisplatin/taxol chemotherapy, with clinical
assessment after 3 and 6 cycles.
Radiotherapy Treatment
Radiotherapy treatment consisted of daily EBRT 23 × 2Gy
for pelvic fields or 28 × 1.8Gy if the para-aortal region
was included in the field. EBRT was delivered using 3D
conformal techniques until 2011, after which intensity modulated
radiotherapy (IMRT) was gradually introduced. From 2014
onwards VMAT was the preferred technique, because of better
conformity and faster treatment times. From 2011 onwards a
plan-of-the day protocol was introduced (25). A brachytherapy
boost was delivered using a high-dose rate iridium source using
2D planning to point A, with a dose of 2 × 8.5Gy. From
the end of 2012 onwards, image (MRI) guided brachytherapy
(IGBT) was applied with a combined interstitial and intracavitary
approach, delivering 3 or 4 fractions of 7Gy or higher to the
high-risk CTV (26).
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Hyperthermia Treatment
Hyperthermia (HT) was delivered after radiation therapy, a
total of five times during the 5–6 weeks of EBRT. The
BSD-2000 system was used (Pyrexar Medical Corporation,
Salt Lake City, Utah, USA) for all HT treatments, with
the Sigma-60 or Sigma-eye applicator selection depending on
the patients’ size. Intraluminal thermometry was performed
by placing thermometers in rectum, bladder and vagina for
all patients. Until July 2012 thermometry was performed by
using Bowman probes (Pyrexar Medical Corporation, Salt
Lake City, Utah, USA) combined with thermal mapping every
5min during treatment with a step size of 1 cm and a
maximum length of 14 cm. Hereafter temperature measurement
was continuous using multi-sensor fiber optic temperature
probes (FISO Technologies Inc., Québec, QC, Canada) (4–
8 sensor distance between sensors 2 cm). Both systems fulfill
the quality assurance guidelines of European Society for
Hyperthermic Oncology, accuracy of±0.2◦C (27, 28). Of 90min
scheduled treatment time, the first 30min are used to warm
up to intraluminal temperatures of ≥40
◦
C. Then treatment
was continued for 60min aiming for maximum intraluminal
temperatures depending on patient tolerance.
Collection of Patient and Follow-Up Data
The following patient characteristics were extracted from the
patient’s files: age at diagnosis, histology, FIGO stage and
lymph node status. Local FIGO stage was noted. Seven
patients presenting with limited distant metastases, but treated
with curative intent, were recorded as FIGO IVB. Induction
chemotherapy was noted. Radiotherapy and HT treatment
characteristics were extracted from treatment planning and other
recording systems.
Pelvic recurrence, distant recurrence, survival status, date
and cause of death, as well as late toxicity data were extracted
and/or retrieved from patient records, referring hospitals, general
physicians and the civil registry. Late toxicity, occurring and/or
persisting after 6 months following treatment, was scored
according to CTCAE v4.0. Only high-grade (equal or higher than
grade 3) toxicities were extracted, as these events are clinically
most relevant and most reliably extracted retrospectively.
Hyperthermia Treatment Parameters
Hyperthermia treatment characteristics collected were the
number of hyperthermia sessions, CEM43T90, TRISE and
treatment duration. The CEM43T90 is the mean cumulative
equivalent minutes of T90 (temperature reached in at least
90% of measurement locations) at 43◦C. TRISE is a thermal
dose parameter based on the temperature exceeded by 50% of
measurement sites and duration of heating (15, 29).
The time interval between EBRT and HT was defined as the
time (in minutes) between the first beam-on of the radiotherapy
treatment and the start of the heating (power on HT device).
As multiple HT treatments are delivered over the course of
treatment, the mean time interval between HT and EBRT
treatment over all hyperthermia treatments was calculated. In
patients in which more than 50% of the time intervals could not
be reconstructed, the time interval was noted as missing.
TABLE 1 | General characteristics of the cohort.
Characteristic Categories Value
PATIENT/TUMOR CHARACTERISTICS
Age (years) 55 (IQR 44.0 – 68.8)
Histology Adeno 40 (10.0%)
Squamous 342 (85.5%)
Other 18 (4.5%)
FIGO stage IB 46 (11.5%)
IIA 15 (3.8%)
IIB 174 (43.5%)
IIIA 18 (4.5%)
IIIB 102 (25.5%)
IVA 38 (9.5%)
IVB 7 (1.8%)
Lymphadenopathy Negative 197 (49.3%)
Iliac 139 (34.8%)
PAO 61 (15.3%)
Missing 3 (0.8%)
Induction chemotherapy No 299 (74.8%)
Yes 101 (25.3%)
RADIATION THERAPY CHARACTERISTICS
Radiation technique 3DCRT 308 (77.0%)
IMRT 50 (12.5%)
VMAT 42 (10.5%)
Radiation field Pelvic 287 (71.8%)
Pelvic + PAO 113 (28.3%)
Brachytherapy use No 30 (7.5%)
Yes 369 (92.3%)
Missing 1 (0.3%)
Image (MRI) guided brachytherapy No 334 (83.5%)
Yes 66 (16.5)
HYPERTHERMIA TREATMENT CHARACTERISTICS
N of treatments 2 10 (2.5%)
3 11 (2.8%)
4 50 (12.5%)
5 329 (82.3%)
Cumulative TRISE (degrees Celsius) 3.46 (2.93-3.86)
Missing 27 (6.8%)
Cumulative CEM43T90(minutes) 3.40 (IQR 1.89–5.83)
Missing 27 (6.8%)
Treatment duration (minutes) 90.0 (IQR 88.0-90.0)
Missing 27 (6.8%)
Mean time interval (minutes) 74.0 (IQR 62.0-94.0)
Missing 8 (2%)
Statistical Analysis
LC, disease free survival (DFS), DSS and OS were calculated
from start date of radiotherapy until event. LC was noted
as “failed” when a physician diagnosed a local recurrence
either clinically or with imaging (CT/MRI). For DFS, an
event was defined as the occurrence of either local or distant
recurrence. Patients were censored for local or distant control
after the last visit of any physician specifically examining
for recurrent disease. For DSS and OS, patients without
an event were censored on the day the civil registry was
Frontiers in Oncology | www.frontiersin.org 3 March 2019 | Volume 9 | Article 134
Kroesen et al. RT-HT Outcome Independent of Time-Interval
FIGURE 1 | KM analysis of low and high time interval and TRISE. KM-curves for low and high time interval and TRISE for LC (A), DFS (B), DSS (C), and OS (D) were
compared using log-rank test.
consulted. LC, DFS, DSS, OS were analyzed using the Kaplan–
Meier method and statistical differences between groups were
determined using the log-rank test. A p-value of ≤ 0.05
was considered statistically significant. For KM analyses per
time period, the cohort was divided into 5-year periods.
Differences in continuous factors between groups were analyzed
using the Mann-Whitney U test. Differences in categorical
factors between groups were analyzed using the Chi-Square
of Fisher’s exact test. Hazard ratio (HR) and 95% confidence
interval (CI) for various covariates were obtained by univariate
Cox proportional hazards analyses. For categorical values,
all categories were compared to the index category. In case
of small numbers of patients per category of a categorical
variable, combinations were made where statistically possible
and clinically reasonable to prevent too small subcategories in
the analyses. Covariates were taken into multivariable analysis
based on clinical experience and a p-value ≤ 0.20 in univariate
analysis. A backward selection procedure was applied with p <
0.05 as a threshold to find the combination of factors that have
independent prognostic value. All analyses were performed using
IBM SPSS statistics version 24.0 software package (SPSS Inc.,
Chicago, IL, USA).
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TABLE 2 | Comparison of low and high TRISE and low and high time interval groups.
Characteristic Category Low TRISE
(n =186)
High TRISE
(n = 187)
p-value Low time
interval (n= 192)
High time interval
(n= 200)
p-value
Age (years) 52.0
(IQR 39.8–66.0)
59.0
(IQR 49.0–72.0)
<0.001 53.5
(IQR 44.0–66.0)
57.0
(IQR 44.0–71.0)
0.118
Histology 0.229 0.504
Adeno 15 (8.1%) 23 (12.3%) 22 (11.5%) 17 (8.5%)
Squamous 164 (88.2%) 153 (81.8%) 160 (83.3%) 175 (87.5%)
Other 7 (3.8%) 11 (5.9%) 10 (5.2%) 8 (4.0%)
FIGO stage 0.093 0.513
IB 27 (14.5%) 14 (7.5%) 27 (14.1%) 17 (8.5%)
IIA 6 (3.2%) 7 (3.7%) 6 (3.1%) 9 (4.5%)
IIB 68 (36.6%) 93 (49.7%) 86 (44.8%) 87 (43.5%)
IIIA 9 (4.8%) 9 (4.8%) 10 (5.2%) 8 (4.0%)
IIIB 48 (25.8%) 47 (25.1%) 42 (21.9%) 55 (27.5%)
IVA 24 (12.9%) 14 (7.5%) 17 (8.9%) 21 (10.5%)
IVB 4 (2.2%) 3 (1.6%) 4 (2.1%) 3 (1.5%)
Lymphadenopathy 0.366 0.003
Negative 98 (53.3%) 86 (46.2%) 81 (42.2%) 111 (56.3%)
Iliac 61 (33.2%) 68 (36.6%) 71 (37.0%) 66 (33.5%)
PAO 25 (13.6%) 32 (17.2%) 40 (20.8%) 20 (10.2%)
Induction 0.576 < 0.001
chemotherapy No 140 (75.3%) 136 (72.7%) 126 (65.6%) 166 (83.0%)
Yes 46 (24.7%) 51 (27.3%) 66 (34.4%) 34 (17.0%)
Radiation technique 0.283 0.001
3DCRT 146 (78.5%) 135 (72.2%) 137 (71.4%) 163 (81.5%)
IMRT 20 (10.8%) 30 (16.0%) 23 (12.0%) 27 (13.5%)
VMAT 20 (10.8%) 22 (11.8%) 32 (16.7%) 10 (5.0%)
Radiation field 0.148 0.978
Pelvic 138 (74.2%) 126 (67.4%) 138 (71.9%) 144 (72.0%)
Pelvic + PAO 48 (25.8%) 61 (32.6%) 54 (28.1%) 56 (28.0%)
IGBT use 0.805 0.038
No 154 (82.8%) 153 (81.8%) 152 (79.2%) 174 (87.0%)
Yes 32 (17.2%) 34 (18.2%) 40 (20.8%) 26 (13.0%)
No of treatments <0.001 0.253
2 7 (3.8%) 0 (0%) 3 (1.6%) 7 (3.5%)
3 9 (4.8%) 0 (0%) 3 (1.6%) 6 (3.0%)
4 42 (22.6%) 5 (2.7%) 25 (13.0%) 23 (11.5%)
5 128 (68.8%) 182 (97.3%) 161 (83.9%) 164 (82.0%)
Cumulative CEM43T90 <0.001 0.764
(minutes) 2.05
(IQR 1.20–3.01)
5.69
(IQR 3.9–7.64)
3.55
(IQR 2.03–5.61)
3.14
(IQR 1.66–6.2)
Cumulative TRISE 0.656
(degrees Celsius) 3.44
(IQR 2.93–3.87)
3.51
(IQR 2.93–3.88)
Time interval (minutes) 0.347
72.5
(IQR 62.0–92.5)
75.0
(IQR 62.0–95.5)
Comparison of patients divided over the median TRISE and time interval.
RESULTS
General Characteristics of the Cohort
Four hundred patients were included in the analysis. General
characteristics of the entire cohort are listed in Table 1. 40
(10.0%) patients had an adenocarcinoma and 342 (85.5%)
had a squamous cell carcinoma. Eighteen patients (4.5%) had
another histology, but were primarily diagnosed as having a
cervix uterus origin. The median time interval between start of
radiotherapy and start of hyperthermia was 74min (interquartile
range (IQR) 62–94min) (Table 1). Median follow-up for local
and distant recurrence was 57 months (IQR 31–81 months).
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FIGURE 2 | KM analysis of quartile time interval groups. KM-curves for quartiles of the time interval and for LC(A), DFS (B), DSS (C), and OS (D) were compared
using log-rank test.
Median follow-up for survival was 106 months (IQR 52–160
months). There were 113 cases with a local recurrence out of 175
cases with any recurrence. There were 151 disease specific deaths
out of 218 total deaths.
One time interval could not be reconstructed in 10.0% and
two time intervals in 2.0% of patients. In these cases, the mean
time interval was calculated using the available interval times. In
8 cases more than 50% of the potential time intervals could not
be reconstructed. Temperature data were system-lost in 27 cases.
Hence, 373 cases were included in the analysis of thermal dose
and 392 for the time interval.
Kaplan-Meier Analysis of the Effect of
Time Interval and Thermal Dose
To determine the effect of time interval and thermal dose on
clinical outcome, we divided the cohort over the median of
the time interval (74min), TRISE (3.46◦C) and CEM43T90
(3.40min). For the time interval no effect was observed for any of
the outcome measures (Figure 1). Figure 1 shows that a higher
thermal dose, expressed as TRISE, corresponded to improved
outcome for all outcome measures. This effect was statistically
significant for LC and DFS. For the thermal dose parameter
CEM43T90, KM curves for LC and DFS showed no significant
differences, see Supplementary Figure 1.
We compared the groups higher and lower than median time
interval and TRISE for equal distribution of other prognostic
factors (Table 2). Patients in the high TRISE group were
significantly older and had more HT treatments (Table 2). In
the low time interval group significantly more patients were
diagnosed with para-aortic lymphadenopathy (20.8 vs. 10.2%)
compared to the high time interval group, more patients were
treated with induction chemotherapy (34.4 vs. 17.0%, p ≤ 0,001)
and more with VMAT (16.7 vs. 5.0%, p = 0.001) and IGBT
(20.8 vs. 13.0%, p = 0.038). These differences are explained
by the length of the time interval, which became shorter over
time (Supplementary Figure 2). KM analyses performed in four
different time periods showed no differences in LC between high
and low time interval patient groups (Supplementary Figure 3),
as well as in DFS, DSS and OS (data not shown). In order to
determine the effect of very short or very long time intervals,
cases were divided over the quartiles of the time interval. Again
no differences were observed for LC, DFS, DSS and OS between
the four time interval groups (Figure 2).
Univariate and Multivariate Cox
Proportional Hazard Analysis
Using univariate Cox proportional hazards regression analysis
the influence of known prognostic factors, time interval and
thermal dose on LC, DFS, DSS, andOSwas determined (Table 3).
The time interval showed no effect on LC, DFS, DSS, and
OS with Hazard Ratios of 1. Histology (squamous cell vs.
adenocarcinoma; HR 0.48; 95% CI 0.29–0.81), FIGO stage (FIGO
IIIA+ IIIB vs. FIGO IB; HR 2.72; 95% CI 1.37–5.39), CEM43T90
(HR 0.93; 95% CI 0.87–0.99), TRISE (HR 0.67; 95% CI 0.52–0.86)
and IGBT (HR 0.41; 95%CI 0.21–0.82) showed a significant effect
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TABLE 3 | Univariate and multivariate Cox regression analysis.
Univariate
analysis
Unit variable
increase
LC DFS DSS OS
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age years 1.00
(0.98–1.01)
0.547 1.00
(0.99–1.01)
0.967 1.00
(0.99–1.01)
0.930 1.02
(1.01–1.03)
<0.001
Histology 0.016 0.014 0.199 0.077
squamous vs.
adeno
0.48
(0.29–0.81)
0.006 0.54
(0.3–0.82)
0.004 0.65
(0.41–1.05)
0.077 0.63
(0.42–0.94)
0.025
other vs. adeno 0.77
(0.32–1.86)
0.559 0.72
(0.34–1.55)
0.77
(0.34–1.76)
0.541 0.74
(0.37–1.49)
0.403
FIGO stage <0.001 <0.001 <0.001 <0.001
IIA+ IIB vs. IB 1.15
(0.58–2.28)
0.695 1.32
(0.76–2.31)
0.322 1.34
(0.72–2.50)
0.349 1.70
(0.99–2.94)
0.057
IIIA + IIIB vs. IB 2.72
(1.38–5.39)
0.004 2.63
(1.50–4.60)
0.001 2.98
(1.60–5.53)
0.001 3.36
(1.94–5.84)
<0.001
IVA + IVB vs. IB 1.38
(0.58–3.33)
0.470 1.69
(0.85–3.35)
0.135 2.10
(1.00–4.40)
0.050 2.81
(1.49–5.29)
0.001
Lymphadenopathy 0.201 0.360 0.268 0.587
iliac vs. negative 1.38
(0.93–2.06)
0.114 1.22
(0.87–1.69)
0.249 1.14
(0.79–1.64)
0.482 0.85
(0.63–1.16)
0.853
PAO vs. negative 0.92
(0.51–1.66)
0.768 1.29
(0.85–1.97)
0.231 1.43
(0.93–2.21)
0.106 0.97
(0.66–1.42)
0.966
Time interval minutes 1.00
(0.99–1.01)
0.565 1.00
(0.99–1.01)
0.597 1.00
(0.99–1.01)
0.655 1.00
(0.99–1.00)
0.855
CEM43T90 minutes 0.93
(0.87–1.00)
0.035 0.95
(0.90–1.00)
0.053 0.96
(0.91–1.02)
0.155 1.01
(0.97–1.01)
0.491
TRISE degrees Celsius 0.67
(0.52–0.86)
0.002 0.75
(0.60–0.92)
0.006 0.73
(0.58–0.91)
0.006 0.80
(0.65–0.96)
0.016
IGBT use yes vs. no 0.41
(0.21–0.82)
0.011 0.56
(0.34–0.91)
0.020 0.38
(0.20–0.73)
0.003 0.43
(0.25–0.74)
0.002
MULTIVARIATE ANALYSIS
Histology 0.010 0.024 n.s. 0.071
squamous vs.
adeno
0.45
(0.26–0.78)
0.004 0.53
(0.33–0.85)
0.008 0.603
(0.39–0.94)
0.024
other vs. adeno 0.65
(0.29–1.46)
0.587 0.74
(0.34–1.62)
0.454 0.75
(0.36–1.54)
0.428
FIGO stage 0.010 0.002 <0.001 <0.001
IIA+ IIB vs. IB 1.50
(0.72–3.11)
0.278 1.69
(0.92–3.10)
0.090 1.82
(0.92–3.61)
0.086 1.98
(1.10–3.58)
0.024
IIIA + IIIB vs. IB 2.80
(1.34–5.84)
0.006 2.86
(1.55–5.27)
0.001 3.54
(1.78–7.07)
<0.001 3.22
(1.77–5.85)
<0.001
IVA + IVB vs. IB 1.74
(0.70–4.30)
0.233 2.03
(0.98–4.17)
0.055 2.45
(1.11–5.37)
0.026 3.38
(1.74–6.60)
<0.001
Lymphadenopathy 0.031 0.051 0.011 n.s.
iliac vs. negative 1.81
(1.16–2.81)
0.009 1.42
(0.99–2.05)
0.059 1.48
(0.99–2.20)
0.057
PAO vs. negative 1.29
(0.70–2.39)
0.419 1.65
(1.05–2.58)
0.031 2.00
(1.25–3.19)
0.004
TRISE degrees celsius 0.65
(0.50–0.84)
0.001 0.72
(0.58–0.89)
0.003 0.71
(0.57–0.90)
0.004 0.79
(0.65–0.96)
0.019
IGBT use yes vs. no 0.43
(0.21–0.97)
0.019 0.58
(0.35–0.96)
0.035 0.41
(0.21–0.78)
0.007 0.46
(0.27–0.81)
0.006
CEM43T90 * minutes 0.92
(0.85–0.99)
0.019 0.94
(0.89–0.99)
0.019 0.94
(0.89–1.00)
0.051 n.s.
Cox proportional hazard analysis for LC, DFS, DSS, and OS. * In multivariate analysis using CEM43T90, other factors showed similar results compared to results shown for TRISE.
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on LC in univariate analysis. FIGO stage, TRISE, and IGBT also
showed a significant effect on DFS, DSS, and OS.
Multivariate Cox analyses were performed (Table 3). As
CEM43T90 and TRISE are both indicators of thermal dose, these
factors were introduced separately into the analyses. Histology
(squamous cell vs. adenocarcinoma; HR 0.45; 95% CI 0.26–0.78),
FIGO stage (FIGO IIIA + IIIB vs. FIGO IB; HR 2.80; 95% CI
1.34–5.84), lymphadenopathy (iliac vs. negative; HR 1.80; 95% CI
1.16–2.81), CEM43T90 (HR 0.92; 95% CI 0.85–0.99), TRISE (HR
0.65; 95% CI 0.50–0.84), and IGBT (HR 0.43; 95% CI 0.21–0.97)
showed a significant effect on LC (Table 3). Note that having
another histology than adeno- or squamous cell carcinoma did
not have a significant effect on any of the clinical endpoints
(Table 3). For DSS, independent prognostic factors were FIGO
stage, lymphadenopathy, TRISE, and IGBT. Time interval was
added to every analysis, but was always removed because
of non-significance.
Effect of Time Interval and Thermal Dose
on Late Toxicity
To determine the effect of time interval and thermal dose
on toxicity, grade 3 or higher late toxicity was analyzed. The
incidence of late toxicity did not differ between low or high
TRISE (10.2 vs. 11.2%, respectively, p = 0.751) or low or
high time interval patients (10.4 vs. 10.5%, respectively, p =
0.978) (Table 4).
DISCUSSION
From this large retrospective cohort study, we conclude that
a time interval between radiotherapy and hyperthermia up to
4 h has no effect on clinical outcome. Other known prognostic
TABLE 4 | Comparison of late toxicity in low and high TRISE and low and high
time interval groups.
Below median
Time Interval
Above median
Time Interval
Total p-value
0.978
No grade 3 or
higher toxicity
172 (89.6%) 179 (89.5%) 351 (89.5%)
Grade 3 or higher
toxicity
20 (10.4%) 21 (10.5%) 41 (10.5%)
Total 192 200 392
Below median
TRISE
Above median
TRISE
Total p-value
0.751
No grade 3 or higher
toxicity
167 (89.8%) 166 (88.8%) 333 (89.3%)
Grade 3 or higher
toxicity
19 (10.2%) 21 (11.2%) 40 (10.7%)
Total 186 187 373
Incidence of grade 3 or higher toxicity in patients with low or high time interval and TRISE.
factors; use of IGBT and the thermal dose did have an effect on
clinical outcome.
Hyperthermia is a potent sensitizer of radiotherapy in cancer
treatment (6, 11, 17, 18, 30–33). Based on preclinical data,
it could be hypothesized that a shorter time interval between
radiotherapy and hyperthermia results in improved clinical
outcome. This is largely based on the -relatively recent- insight
that hyperthermia inhibits DNA repair in combination with
the observation that most DNA damage after radiotherapy is
repaired within 2–6 h (13, 20, 23). Several preclinical studies
have analyzed the influence of the time interval (17, 20, 34).
Li et al showed enhanced cell kill efficacy upon a shorter time
interval (34). Overgaard et al. using a murine model, showed
that at a time interval of 4 h, the normal tissue damage is
minimized compared to the tumor damage (17). This study
also showed that a shorter time interval increased tumor cell
killing, but at the cost of increased normal tissue toxicity. The
drawback of these two studies is that the target temperatures
used, exceed those generally measured in the clinic. More
recently, two cervical carcinoma cell lines were treated with
hyperthermia and radiotherapy at different time intervals and
target temperatures (20). There was a small increase in cell killing
at shorter time intervals, but the effect was less apparent than in
previous studies (17, 34). Finally, preclinical data generated at our
institute indicate no enhanced effect of a shorter time interval
on tumor cell kill (personal communication R. Kanaar, Dept. of
Molecular Genetics).
There are few clinical studies which have investigated the
clinical relevance of the time interval between radiotherapy and
hyperthermia (21, 22). Arcangeli et al showed that skin toxicity
was reduced with an interval of 4 h, compared to simultaneous
application (21). Lindholm et al compared short and long time
intervals in patients with superficial tumors (22). In both studies
patient numbers were too small to draw firm conclusions. More
recently, in a cohort of 58 primary cervical carcinoma patients,
a significant association between a lower than median time
interval and improved LC and OS was observed (23). To explain
for these different findings, firstly patient characteristics may
be different between the two cohorts. In the cohort of Van
Leeuwen et al. patients are only indicated for thermoradiotherapy
when chemoradiation was not possible due to renal function
impairment, co-morbidity or age. Therefore, these patients are
potentially more frail compared to the patients in our cohort.
Second, it is possible that thermal dose was higher compared
to our cohort, leading to a more pronounced biological effect
of the time interval in the cohort of Van Leeuwen. Finally, in
the study by Van leeuwen, following dichotomization of the time
interval for KM analysis, the dichotomized time interval was also
used in Cox proportional hazard analysis. Instead, we used the
continuous value of the time interval in Cox analysis, as this is
more informative and less sensitive to false positive results (35).
Future clinical studies, preferably prospective, should provide a
more definitive answer to this relevant clinical issue.
Besides the abovementioned inhibition of DNA repair,
hyperthermia can also sensitize tumor cells to radiotherapy
through various other mechanisms. These mechanisms include
increased oxygenation, induction of direct tumor cell death
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and immune stimulation (12). Little is known about the
exact biological and physiological mechanisms that constitute
hyperthermia’s proven clinical effectiveness. Increased perfusion
and thus increased oxygenation can be expected at temperatures
≥39
◦
C and may hold for many hours after treatment (36,
37). The direct hyperthermia-induced cytotoxicity seems to
come in play at temperatures of ≥40
◦
C. This effect is short-
lived after treatment but results in spatial cooperation as it
mainly effects cancer cells that are relatively insensitive to the
effects of radiotherapy and chemotherapy (19, 38, 39). Studies
investigating the effect of local or loco-regional hyperthermia
on the immune system have not yet looked into the time or
temperature dependency to our knowledge (40). The relative
contribution of these effects to the clinical effect of hyperthermia
is unknown. Our finding of a null-effect of the time interval
could be interpreted as that DNA repair inhibition is relatively
unimportant for the clinical hyperthermia effect. But it could
also imply that in patients, it takes longer before the DNA repair
inhibition effect disappears, compared to in vitro studies.
A limitation of our study is the retrospective setup, with
the potential for confounding, data misinterpretation and data
loss. The latter could be relevant for the collection of the
late toxicity data in our study, as it was not recorded in a
standardized manner at Erasmus MC Cancer Institute during
the time of inclusion. Therefore, we chose not to include
Grade 1–2 late toxicities as these might have been recorded
incompletely. Grade 3 or higher toxicities are more likely
to be recorded as by definition, a medical intervention is
required. As potential miss of toxicity is not related to the
studied factors (TRISE, time interval), we do not expect the
statistical analysis to be influenced by this potential miss
of data.
CONCLUSIONS
In contrast to thermal dose, there is no effect of the time interval
between radiotherapy and hyperthermia on clinical outcome in
primary cervical carcinoma patients. The clinical consequence
of this study is that our current recommendation to apply
hyperthermia within 4 h after radiation was and remains valid
for cervical carcinoma patients treated with thermoradiotherapy.
These finding are also relevant for the, mostly centralized, clinical
hyperthermia units, as patients can be re-assured that their
outcome is not affected by travel times up to 4 h.
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